



Chinese Pharmaceutical Association  
Institute of Materia Medica, Chinese Academy of Medical Sciences

Acta Pharmaceutica Sinica B

[www.elsevier.com/locate/apSB](http://www.elsevier.com/locate/apSB)  
[www.sciencedirect.com](http://www.sciencedirect.com)



## CORRECTION

# Author correction to “DNA damage repair promotion in colonic epithelial cells by andrographolide downregulated cGAS–STING pathway activation and contributed to the relief of CPT-11-induced intestinal mucositis” [Acta Pharmaceutica Sinica B 12 (2022) 262–273]



Yuanyuan Wang<sup>a,b,†</sup>, Bin Wei<sup>a,c,†</sup>, Danping Wang<sup>a,b</sup>, Jingjing Wu<sup>c</sup>, Jianhua Gao<sup>d</sup>, Haiqing Zhong<sup>d</sup>, Yang Sun<sup>d</sup>, Qiang Xu<sup>d</sup>, Wen Liu<sup>d,\*</sup>, Yanhong Gu<sup>a,b,\*</sup>, Wenjie Guo<sup>d,\*</sup>

<sup>a</sup>Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China

<sup>b</sup>Cancer Rehabilitation Center, Jiangsu Province Hospital, Nanjing 210029, China

<sup>c</sup>Department of Oncology, the Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University, Huai'an 223300, China


<sup>d</sup>State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing 210023, China

The authors regret that there was a mistake in Fig. 1F (Tunel staining): the images for CPT-11+Andro 25 mg/kg group were mistakenly linked to the images for CPT-11 group when combined in the software Adobe Illustrator. The authors revise the image of the CPT-11+Andro 25 mg/kg group. The revisions do not affect any results and conclusions of the current work. We have provided

the original data of this figure to Editorial Office, and the corresponding authors or the Editorial Office can be contacted for original data access.

The authors sincerely apologize for any inconvenience caused to the journal and readers.

Fig. 1F is revised as:



DOI of original article: <https://doi.org/10.1016/j.apSB.2021.03.043>.

\*Corresponding authors.

E-mail addresses: [liuwen1849@126.com](mailto:liuwen1849@126.com) (Wen Liu), [guyhphd@163.com](mailto:guyhphd@163.com) (Yanhong Gu), [guowj@nju.edu.cn](mailto:guowj@nju.edu.cn) (Wenjie Guo).

†These authors made equal contributions to this work.

Peer review under the responsibility of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.

<https://doi.org/10.1016/j.apSB.2023.05.008>

2211-3835 © 2023 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).